Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab131241)
Key features and details
- Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214)
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-VEGF Receptor 2 (phospho Y1214) antibody
See all VEGF Receptor 2 primary antibodies -
Description
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide corresponding to Human VEGF Receptor 2 (phospho Y1214) conjugated to keyhole limpet haemocyanin.
-
Positive control
- MCF cells; SKOV3 cell extracts; Human breast carcinoma tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.88% Sodium chloride
PBS without Mg2+ and Ca2+ -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
ab131241 was purified by affinity chromatography using epitope-specific phosphopeptide. Non-phospho specific antiibodies were removed by chromatography using non-phosphorpetide. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab131241 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB |
1/500 - 1/1000. Predicted molecular weight: 151 kDa.
|
|
| IHC-P |
1/50 - 1/100.
|
|
| ICC/IF |
1/100 - 1/200.
|
| Notes |
|---|
|
WB
1/500 - 1/1000. Predicted molecular weight: 151 kDa. |
|
IHC-P
1/50 - 1/100. |
|
ICC/IF
1/100 - 1/200. |
Target
-
Function
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3791 Human
- Omim: 191306 Human
- SwissProt: P35968 Human
- Unigene: 479756 Human
-
Alternative names
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
Images
-
Western blot - Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab131241)All lanes : Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab131241) at 1/500 dilution
Lane 1 : SKOV3 cell extract
Lane 2 : SKOV3 cell extract with blocking peptide
Predicted band size: 151 kDa -
Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab131241)Immunofluorescence analysis of methanol-fixed MCF cells labelling VEGF Receptor 2 (phospho Y1214) with ab131241 at 1/100 dilution. -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab131241)Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labelling VEGF Receptor 2 (phospho Y1214) with ab131241 at 1/50 dilution. Right panel was preincubated with blocking peptide.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab131241 has been referenced in 5 publications.
- Lin J et al. Inhibition of CD146 attenuates retinal neovascularization via vascular endothelial growth factor receptor 2 signalling pathway in proliferative diabetic retinopathy. Acta Ophthalmol 100:e899-e911 (2022). PubMed: 34477295
- Rodríguez-Remírez M et al. Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas. Neuroendocrinology 111:146-157 (2021). PubMed: 31991407
- Zhang W et al. Study of injectable Blueberry anthocyanins-loaded hydrogel for promoting full-thickness wound healing. Int J Pharm 586:119543 (2020). PubMed: 32561307
- Ding Q et al. Lack of endogenous parathyroid hormone delays fracture healing by inhibiting vascular endothelial growth factor-mediated angiogenesis. Int J Mol Med 42:171-181 (2018). PubMed: 29620150
- Liebler S et al. Towards a biofunctionalized vascular prosthesis: immune cell trapping via a growth factor receptor. J Tissue Eng Regen Med 11:2699-2709 (2017). PubMed: 27225726